Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Deloitte
Accenture
Covington
Merck
Healthtrust
Mallinckrodt
McKesson
US Army

Generated: May 22, 2018

DrugPatentWatch Database Preview

Synergy Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for SYNERGY PHARMS, and when can generic versions of SYNERGY PHARMS drugs launch?

SYNERGY PHARMS has one approved drug.

There are seven US patents protecting SYNERGY PHARMS drugs.

There are forty-one patent family members on SYNERGY PHARMS drugs in thirteen countries.

Summary for Synergy Pharms
International Patents:41
US Patents:7
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Synergy Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Synergy Pharms TRULANCE plecanatide TABLET;ORAL 208745-001 Jan 19, 2017 RX Yes Yes 7,799,897 ➤ Sign Up Y ➤ Sign Up
Synergy Pharms TRULANCE plecanatide TABLET;ORAL 208745-001 Jan 19, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up
Synergy Pharms TRULANCE plecanatide TABLET;ORAL 208745-001 Jan 19, 2017 RX Yes Yes 7,041,786 ➤ Sign Up Y ➤ Sign Up
Synergy Pharms TRULANCE plecanatide TABLET;ORAL 208745-001 Jan 19, 2017 RX Yes Yes 9,919,024 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Synergy Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,114,831 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Deloitte
Chubb
McKesson
Citi
Mallinckrodt
Colorcon
Julphar
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.